Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
122.97
+0.12 (0.10%)
Dec 20, 2024, 4:00 PM EST - Market closed
Jazz Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 3,993 | 3,834 | 3,659 | 3,094 | 2,364 | 2,162 | Upgrade
|
| Revenue Growth (YoY) | 5.23% | 4.78% | 18.26% | 30.91% | 9.34% | 14.32% | Upgrade
|
| Cost of Revenue | 294.67 | 284.13 | 267.13 | 217.68 | 148.92 | 127.93 | Upgrade
|
| Gross Profit | 3,698 | 3,550 | 3,392 | 2,877 | 2,215 | 2,034 | Upgrade
|
| Selling, General & Admin | 1,376 | 1,307 | 1,399 | 1,399 | 879.85 | 761.87 | Upgrade
|
| Research & Development | 834.34 | 823.89 | 555.41 | 476.33 | 309.76 | 274.8 | Upgrade
|
| Operating Expenses | 2,830 | 2,739 | 2,553 | 2,401 | 1,449 | 1,391 | Upgrade
|
| Operating Income | 867.63 | 810.73 | 839.14 | 475.26 | 765.46 | 642.35 | Upgrade
|
| Interest Expense | -352.47 | -354.54 | -299.74 | -280.57 | -110.81 | -72.26 | Upgrade
|
| Interest & Investment Income | 95.3 | 65.1 | 11.5 | 1.8 | 11.1 | - | Upgrade
|
| Earnings From Equity Investments | -2.11 | -3.01 | -9.92 | -0.71 | -2.96 | -4.09 | Upgrade
|
| Currency Exchange Gain (Loss) | 7.47 | 8.79 | -19.01 | -4.35 | -3.27 | -5.81 | Upgrade
|
| EBT Excluding Unusual Items | 615.83 | 527.07 | 521.97 | 191.43 | 659.52 | 560.19 | Upgrade
|
| Merger & Restructuring Charges | -129.57 | -151.45 | -326.88 | -304.99 | - | - | Upgrade
|
| Asset Writedown | -61.7 | -61.7 | -133.65 | - | -136.14 | - | Upgrade
|
| Pretax Income | 396.55 | 294.92 | -382.71 | -113.55 | 272.13 | 450.21 | Upgrade
|
| Income Tax Expense | -66.61 | -119.91 | -158.65 | 216.12 | 33.52 | -73.15 | Upgrade
|
| Earnings From Continuing Operations | 463.16 | 414.83 | -224.06 | -329.67 | 238.62 | 523.37 | Upgrade
|
| Net Income | 463.16 | 414.83 | -224.06 | -329.67 | 238.62 | 523.37 | Upgrade
|
| Net Income to Common | 463.16 | 414.83 | -224.06 | -329.67 | 238.62 | 523.37 | Upgrade
|
| Net Income Growth | 479.28% | - | - | - | -54.41% | 17.06% | Upgrade
|
| Shares Outstanding (Basic) | 62 | 63 | 63 | 60 | 56 | 57 | Upgrade
|
| Shares Outstanding (Diluted) | 68 | 72 | 63 | 60 | 57 | 58 | Upgrade
|
| Shares Change (YoY) | -2.29% | 15.23% | 4.77% | 5.62% | -1.79% | -6.00% | Upgrade
|
| EPS (Basic) | 7.43 | 6.55 | -3.58 | -5.52 | 4.28 | 9.22 | Upgrade
|
| EPS (Diluted) | 7.04 | 6.10 | -3.58 | -5.52 | 4.22 | 9.09 | Upgrade
|
| EPS Growth | 458.10% | - | - | - | -53.58% | 24.52% | Upgrade
|
| Free Cash Flow | 1,130 | 1,068 | 1,243 | 750.87 | 884.64 | 736.27 | Upgrade
|
| Free Cash Flow Per Share | 16.60 | 14.82 | 19.87 | 12.58 | 15.65 | 12.79 | Upgrade
|
| Gross Margin | 92.62% | 92.59% | 92.70% | 92.97% | 93.70% | 94.08% | Upgrade
|
| Operating Margin | 21.73% | 21.14% | 22.93% | 15.36% | 32.39% | 29.71% | Upgrade
|
| Profit Margin | 11.60% | 10.82% | -6.12% | -10.65% | 10.10% | 24.21% | Upgrade
|
| Free Cash Flow Margin | 28.30% | 27.86% | 33.97% | 24.27% | 37.43% | 34.06% | Upgrade
|
| EBITDA | 1,518 | 1,449 | 1,469 | 1,028 | 1,044 | 1,013 | Upgrade
|
| EBITDA Margin | 38.03% | 37.80% | 40.13% | 33.21% | 44.16% | 46.84% | Upgrade
|
| D&A For EBITDA | 650.85 | 638.7 | 629.47 | 552.48 | 278.25 | 370.16 | Upgrade
|
| EBIT | 867.63 | 810.73 | 839.14 | 475.26 | 765.46 | 642.35 | Upgrade
|
| EBIT Margin | 21.73% | 21.14% | 22.93% | 15.36% | 32.39% | 29.71% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 12.32% | - | Upgrade
|
| Revenue as Reported | 3,993 | 3,834 | 3,659 | 3,094 | 2,364 | 2,162 | Upgrade
|
| Advertising Expenses | - | 92.2 | 108.8 | 161.5 | 99.6 | 65.4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.